Table 2.

Treatment-emergent adverse events in ≥15% of patients

Pembrolizumab (2 mg/kg) + utomilumab (N = 23)
Treatment emergentTreatment related
Adverse eventaAll gradesGrade 3–4bAll gradesGrade 3–4
Fatigue10 (43.5)1 (4.3)8 (34.8)0
Rash10 (43.5)08 (34.8)0
Cough8 (34.8)01 (4.3)0
Decreased appetite7 (30.4)03 (13.0)0
Nausea7 (30.4)03 (13.0)0
Constipation6 (26.1)01 (4.3)0
Pruritus6 (26.1)05 (21.7)0
Pyrexia5 (21.7)03 (13.0)0
Vomiting5 (21.7)01 (4.3)0
Anemia4 (17.4)3 (13)00
Dyspepsia4 (17.4)02 (8.7)0
Upper respiratory tract infection4 (17.4)000
  • aNone of the patients discontinued due to treatment-related adverse events.

  • bTreatment-related grade 3 adverse events reported in this study included adrenal insufficiency and hypokalemia (n = 1 each).